🇺🇸 FDA
Patent

US 10940168

Method of treating Bruch's membrane hypofunction disease

granted A61KA61K35/616A61K36/258

Quick answer

US patent 10940168 (Method of treating Bruch's membrane hypofunction disease) held by Altregen Co., Ltd. expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Altregen Co., Ltd.
Grant date
Tue Mar 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
10
CPC classes
A61K, A61K35/616, A61K36/258, A61K9/0048, A61P